Navigation Links
Study IDs Gene Variants Tied to Sudden Cardiac Death
Date:3/23/2009

Finding could prevent fatal arrhythmias by limiting meds in those with risk factor

MONDAY, March 23 (HealthDay News) -- Fourteen common genetic variants associated with a risk factor for sudden cardiac death have been identified by researchers who analyzed genetic data from more than 13,000 people.

The gene variants they identified influence the QT interval measured on electrocardiograms (EKGs) routinely used by doctors to assess patients' heart health. The QT interval is the time from the beginning of electrical activation of the heart to the end of electrical relaxation, according to background information in a news release about the study.

The researchers said their findings, published online in Nature Genetics, could help prevent heart arrhythmia and prevent sudden cardiac death by limiting the use of medications that affect QT interval in people with these 14 gene variants, which are located in 10 different gene regions.

"It is well-established that prolongation of the QT interval in the general population is a potent and heritable risk factor for sudden death. In addition, QT prolongation results from medications leading to drug-induced cardiac arrhythmias and sudden death. This is a cardiotoxic side effect of scores of medications in widespread use and has been a major barrier to the development of novel drugs," study author Dr. Christopher Newton-Cheh, of the Massachusetts General Hospital (MGH) Center for Human Genetic Research and Cardiovascular Research Center, said in an MGH news release.

"From studies of families with congenital long-QT syndrome, we know that rare mutations with strong effects on ion channel function lead to QT prolongation and sudden death. But the common genetic basis for QT prolongation has been very difficult to establish," he said.

A companion study in the same issue of Nature Genetics looked at more than 15,000 people and confirmed 12 of the 14 v
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
2. New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics
3. Study quantifies racial disparities in cancer mortality rates between blacks and whites
4. Herbalife Protein Shake Proven Effective in Clinical Study
5. New study finds daily drinking is biggest risk factor in serious liver disease
6. Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status
7. Mayo Clinic study suggests those who have chronic pain may need to assess vitamin D status
8. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
9. Genetics Should Decide Warfarin Dose, Study Reiterates
10. Cognitive decline begins in late 20s, study suggests
11. Study finds most adolescents sent to group homes still involved with drugs/crime seven years later
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study IDs Gene Variants Tied to Sudden Cardiac Death
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... first time to date, research published in the October ... sought to determine the use of chemotherapy in ... encompassing all patient ages. Prior population-based studies have shown ... cancer patients receive chemotherapy treatment. These studies have previously ...
... Researchers from the Arkansas Epilepsy Program found treatment with ... compared with placebo, for patients with uncontrolled partial-onset seizures ... in Epilepsia , a journal published by Wiley-Blackwell ... Epilepsy affects up to 2% of the worldwide ...
... papillomavirus (HPV) DNA-based testing or visual inspection of the ... had a statistically significant reduction in high grade cervical ... according to a study published online Sept. 30 in ... In many developing countries, especially in ...
... of Health scientists could explain how Salmonella bacteria, a ... In a study published this week in the ... describe finding a reservoir of rapidly replicating Salmonella inside ... cells and are pushed from the epithelial layer by ...
... MEDFORD/SOMERVILLE, Mass.--Researchers from Tufts University School of Engineering and ... precursors to the potent anti-cancer compound Taxol in an ... The findings are significant steps on the way to ... to design new Taxol-like pharmaceuticals. The work ...
... Louisville School of Nursing has earned a $792,000 grant ... Health Resources and Services Administration to develop nursing informatics ... well as practicing nurses from University of Louisville Hospital. ... a tsunami of patient data in order to make ...
Cached Medicine News:Health News:New lung cancer research finds half of advanced lung cancer patients receive chemotherapy 2Health News:Adjunctive rufinamide reduces refractory partial-onset seizures 2Health News:HPV screen-and treat-intervention effective in cervical cancer prevention 2Health News:NIH scientists describe how salmonella bacteria spread in humans 2Health News:Researchers advance biosynthesis of potent anti-cancer drug Taxol 2Health News:UofL School of Nursing awarded grant to fund new informatics education project 2
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
(Date:12/24/2014)... Mass. , Dec. 23, 2014   ... ), a biopharmaceutical company developing therapeutic products for ... Medicines Agency (EMA) of the Marketing Authorization Application ... EMA recently granted the company,s request for accelerated ... EMA,s regulatory review time.   The ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... SANTA ROSA, Calif. , Feb. 16 Osseon Therapeutics ... Europe . The procedures were performed in Milan, Italy ... largest independent medical device distributor in Europe , Osseoplasty cases ... United Kingdom , Germany and Spain . ...
... , CRANBURY, N.J. , Feb. 16 ... the fourth quarter and full year 2009.  The Company also provided ... key strategic priorities for 2010.  Additionally, the Company stated that it ... completing enrollment for its Phase 3 study of Amigal ™ ...
Cached Medicine Technology:Osseon Launches in Europe 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements 11
... with blade. Fiberoptic blades are designed ... allowing you to take advantage of ... from different fitting fiberoptic systems. FOCS™ ... cost effective alternative to expensive fiberoptic ...
... can be used with Portex® reusable or ... blades with long-lasting bronze fiber-optic bundles provide ... routine use., ,The laryngoscope blades are ... from infant to large adult, and in ...
... system. Providing an unobstructed view of the ... many types of intubations., ,A high ... patented Glidescope blade. Clear images are captured ... monitor screen. An LED light source mounted ...
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
Medicine Products: